Greystoke, Alastair

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Messina, C., Giunta, E. F., Signori, A., Rebuzzi, S. E., Banna, G. L., Maniam, A., Buti, S., Cattrini, C., Fornarini, G., Bauckneht, M., et al. (2024) · European Urology Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 39

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

Middleton, G., Robbins, H. L., Fletcher, P., Savage, J., Mehmi, M., Summers, Y., Greystoke, A., Steele, N., Popat, S., Jain, P., et al. (2025) · npj Precision Oncology

Lung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

Cited by 7